Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A S F Doney

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Neuropharmacology|June 25, 2008
The cost of cerebral ischaemiaR W V Flynn, R S M MacWalter, A S F Doney
Diabetic Medicine : a Journal of the British Diabetic Association|August 4, 2009
The Y402H variant of complement factor H is associated with age-related macular degeneration but not with diabetic retinal disease in the Go-DARTS studyA S F Doney, G P Leese, J Olson, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 26, 2006
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetesL A Donnelly, A S F Doney, A T Hattersley, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 23, 2008
Long-term adherence to statin treatment in diabetesL A Donnelly, A S F Doney, A D Morris, et al.
Clinical Pharmacology and Therapeutics|March 3, 2007
PPARG locus haplotype variation and exacerbations in asthmaC N A Palmer, A S F Doney, T Ismail, et al.
Diabetologia|July 12, 2005
The Pro12Ala and C-681G variants of the PPARG locus are associated with opposing growth phenotypes in young schoolchildrenJ E Cecil, B Fischer, A S F Doney, et al.
Diabetologia|January 20, 2004
Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetesA S F Doney, B Fischer, J E Cecil, et al.
Diabetologia|April 13, 2007
TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levelsC H Kimber, A S F Doney, E R Pearson, et al.
Clinical Pharmacology and Therapeutics|December 24, 2010
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS studyL A Donnelly, A S F Doney, R Tavendale, et al.
Clinical Pharmacology and Therapeutics|October 2, 2009
Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS studyK Zhou, L Donnelly, L Burch, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Neuropharmacology|June 25, 2008
The cost of cerebral ischaemiaR W V Flynn, R S M MacWalter, A S F Doney
Diabetic Medicine : a Journal of the British Diabetic Association|August 4, 2009
The Y402H variant of complement factor H is associated with age-related macular degeneration but not with diabetic retinal disease in the Go-DARTS studyA S F Doney, G P Leese, J Olson, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 26, 2006
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetesL A Donnelly, A S F Doney, A T Hattersley, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 23, 2008
Long-term adherence to statin treatment in diabetesL A Donnelly, A S F Doney, A D Morris, et al.
Clinical Pharmacology and Therapeutics|March 3, 2007
PPARG locus haplotype variation and exacerbations in asthmaC N A Palmer, A S F Doney, T Ismail, et al.
Diabetologia|July 12, 2005
The Pro12Ala and C-681G variants of the PPARG locus are associated with opposing growth phenotypes in young schoolchildrenJ E Cecil, B Fischer, A S F Doney, et al.
Diabetologia|January 20, 2004
Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetesA S F Doney, B Fischer, J E Cecil, et al.
Diabetologia|April 13, 2007
TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levelsC H Kimber, A S F Doney, E R Pearson, et al.
Clinical Pharmacology and Therapeutics|December 24, 2010
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS studyL A Donnelly, A S F Doney, R Tavendale, et al.
Clinical Pharmacology and Therapeutics|October 2, 2009
Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS studyK Zhou, L Donnelly, L Burch, et al.
Pageof 2